Airsculpt Technologies (AIRS) AI Stock Analysis

• Market Cap: $107.70M
• Dividend Yield: N/A
• Average Volume (3M): 1.05M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.93
• Revenue Growth: -16.54%
• EPS Growth: -119.56%
• Country: US
• Employees: 389
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): -0.04
• Shares Outstanding: 62,436,670
• 10 Day Avg. Volume: 629,231
• 30 Day Avg. Volume: 1,053,493
• PEG Ratio: -0.47
• Price to Book (P/B): 3.78
• Price to Sales (P/S): 1.66
• P/FCF Ratio: -112.69
• Enterprise Value/Market Cap: 1.73
• Enterprise Value/Revenue: 1.18
• Enterprise Value/Gross Profit: 1.85
• Enterprise Value/Ebitda: 114.71
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $2.50 ▼(-29.97% Downside)
• Action: Reiterated Date: 01/21/26
• Date: Action: Reiterated 01/21/26

The score is primarily constrained by weak financial performance (declining revenue, negative profitability, and negative free cash flow). The latest earnings call reinforces near-term pressure via declining results and reduced revenue outlook, partially balanced by cost actions and debt reduction. Technicals are mixed but still trend-challenged, and valuation is difficult to support given losses and no dividend.

Positive Factors

Debt Reduction / Leverage

Material debt repayment (~$18M YTD) meaningfully improves capital structure and reduces refinancing and interest expense risk. Lower leverage increases financial flexibility to fund remodeling, marketing, or strategic investments and supports execution of the turnaround without immediate external financing.

GLP-1 Market Opportunity

Pivoting to offer GLP-1–related services (skin tightening, excisions) aligns with robust structural demand from rapidly rising GLP-1 prescriptions. This diversifies procedure mix, creates adjacent-service revenue potential, and leverages the existing center footprint for sustainable incremental volumes.

Strengthened Leadership / Governance

Adding an experienced public-market CFO and a multi-site healthcare chairman upgrades governance and financial leadership. Improved capital allocation, reporting rigor, and operational discipline enhance credibility with investors and lenders and help execute center-level optimization and strategic initiatives.

Negative Factors

Declining Revenue and Cases

Sharp revenue and case declines across the core business indicate weakening demand or conversion issues. Persistent top-line contraction undermines scale economics, reduces per-center profitability, pressures margins and cash flow, and limits the company’s ability to invest in marketing or new service rollouts.

Negative Free Cash Flow

Ongoing negative free cash flow and poor cash conversion constrain self-funding of growth and capex. Reliance on external financing or asset sales reduces strategic flexibility, increases funding risk during downturns, and limits ability to scale GLP-1-related initiatives or sustain marketing investments.

Asset Impairments & Center Closure

Closing unprofitable centers and recording impairments signals execution and expansion risk. Write-downs erode invested capital, reflect misallocated prior investments, and raise the chance of further costly adjustments, slowing margin recovery and complicating scaling across new markets or technology projects.

Airsculpt Technologies Business Overview & Revenue Model

Company Description

Airsculpt Technologies (AIRS) is an innovative company that specializes in advanced surgical and non-surgical body contouring procedures. Operating primarily in the healthcare and aesthetics sectors, Airsculpt Technologies offers proprietary technologies and services designed to provide patients with minimally invasive options for body sculpting and fat removal. The company's core product line includes its patented AirSculpt® procedure, which utilizes a unique method to remove unwanted fat while ensuring minimal downtime and optimal results.

How the Company Makes Money

Airsculpt Technologies generates revenue primarily through its surgical and non-surgical body contouring procedures. The company charges patients for each procedure performed, which includes the cost of the technology used, medical staff, and facility fees. Additionally, Airsculpt Technologies may earn income through partnerships with medical practitioners and clinics that offer its services, as well as through training and support programs for those practitioners. The company could also explore potential revenue from licensing its proprietary technology to third-party providers, thereby expanding its market reach and enhancing its earnings.

Airsculpt Technologies Financial Statement Overview

Summary

Financial statements point to ongoing strain: revenue is declining in the TTM period, profitability is weak with negative net and EBIT margins, and free cash flow remains negative despite some improvement. Balance sheet leverage has improved, but negative ROE underscores continued difficulty generating shareholder returns.

Income Statement

Airsculpt Technologies has faced declining revenue growth, with a negative growth rate in the TTM period. The company has struggled with profitability, as indicated by negative net profit margins and EBIT margins. The gross profit margin has significantly decreased from previous years, indicating pressure on cost management.

Balance Sheet

The company's debt-to-equity ratio has improved in the TTM period, suggesting better leverage management compared to previous years. However, the return on equity remains negative, indicating challenges in generating returns for shareholders. The equity ratio is stable, reflecting a balanced asset structure.

Cash Flow

Airsculpt Technologies has shown improvement in free cash flow growth in the TTM period, but the free cash flow remains negative, which is a concern. The operating cash flow to net income ratio is low, indicating inefficiencies in converting income into cash. The free cash flow to net income ratio is also negative, highlighting cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	157.55M	180.35M	195.92M	168.79M	133.31M	62.77M
Gross Profit	100.79M	108.97M	121.91M	110.51M	88.78M	39.30M
EBITDA	1.63M	10.07M	19.74M	4.59M	22.36M	15.67M
Net Income	-17.98M	-8.25M	-4.48M	-14.68M	10.55M	7.58M
Balance Sheet
Total Assets	185.92M	210.00M	204.02M	200.76M	200.55M	179.61M
Cash, Cash Equivalents and Short-Term Investments	5.41M	8.23M	10.26M	9.62M	25.35M	10.38M
Total Debt	84.21M	105.05M	99.67M	107.65M	100.58M	49.77M
Total Liabilities	103.81M	130.71M	120.03M	129.99M	117.03M	55.93M
Stockholders Equity	82.11M	79.29M	83.99M	70.77M	83.53M	123.68M
Cash Flow
Free Cash Flow	2.47M	-2.66M	14.04M	11.53M	19.52M	10.27M
Operating Cash Flow	8.34M	11.35M	23.96M	24.45M	26.63M	13.96M
Investing Cash Flow	-5.87M	-14.01M	-9.92M	-12.92M	-7.12M	-3.69M
Financing Cash Flow	-3.03M	630.00K	-13.39M	-27.26M	-4.55M	-5.02M

Airsculpt Technologies Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.57
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIRS, the sentiment is Negative. The current price of 3.57 is above the 20-day moving average (MA) of 2.22, above the 50-day MA of 2.30, and below the 200-day MA of 5.13, indicating a bearish trend. The MACD of -0.25 indicates Positive momentum. The RSI at 35.04 is Neutral, neither overbought nor oversold. The STOCH value of 13.99 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AIRS.

Airsculpt Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NHC	74 Outperform	$2.44B	24.24	9.94%	1.80%	23.74%	-18.99%
HCSG	73 Outperform	$1.50B	26.24	11.69%	―	6.26%	-19.33%
CYH	60 Neutral	$483.80M	0.93	―	―	0.74%	―
AMN	52 Neutral	$788.28M	-8.18	-35.90%	―	-11.42%	-617.31%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CCRN	48 Neutral	$286.32M	-18.10	-3.76%	―	-22.14%	-787.87%
AIRS	46 Neutral	$107.70M	-5.80	-21.85%	―	-16.54%	-119.56%

Airsculpt Technologies Corporate Events

AirSculpt Technologies Appoints Mike Doyle as Chairman

On November 14, 2025, AirSculpt Technologies appointed Mike Doyle as the Non-Executive Chairman of its Board of Directors. With over 30 years of leadership experience in the multi-center healthcare sector, Doyle’s appointment is expected to guide AirSculpt in its next phase of transformation, leveraging his expertise in building successful multi-site healthcare organizations. This strategic move aims to capture new market opportunities and create value for stakeholders.

The most recent analyst rating on (AIRS) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Airsculpt Technologies stock, see the AIRS Stock Forecast page.

AirSculpt Technologies Appoints New Chief Financial Officer

AirSculpt Technologies announced the appointment of Michael Arthur as Chief Financial Officer, effective January 5, 2026. Arthur, a seasoned executive with experience in public market finance, is expected to enhance the company’s leadership team. The company reported a decline in third-quarter 2025 revenue and case volume compared to the previous year, attributing the revenue drop to timing issues rather than business trajectory. Despite the decline, AirSculpt remains confident in its strategy, focusing on growth opportunities and debt reduction, and anticipates improved sales trends and EBITDA margin expansion in the fourth quarter.

The most recent analyst rating on (AIRS) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Airsculpt Technologies stock, see the AIRS Stock Forecast page.